Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults

Journal of Laryngology and Otology

Volumn 117, Issue 1, 2003, Pages 43-51

  Klossek, Jean Michel ^c   Siegert, R ^d   Nikolaidis, P ^a   Arvis, P ^b   Leberre, M A ^b  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b Bayer Pharma   (France)

^c University of Poitiers   (France)

^d NONE

Author keywords

Antibiotics; Bacterial Infections; Sinusitis

Indexed keywords

MOXIFLOXACIN; TROVAFLOXACIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; TACHYCARDIA; VERTIGO;

ACUTE DISEASE; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MAXILLARY SINUSITIS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NAPHTHYRIDINES; PROSPECTIVE STUDIES; QUINOLINES; TREATMENT OUTCOME;

EID: 0037232760     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/002221503321046630     Document Type: Article

References (25)

1. Glicklich R, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 1995;113:104-9
2. Poole MD. A focus on acute sinusitis in adults: Changes in disease management. Am J Med 1999;106:38S-47S
3. Garcia-Rodriguez JA, Gomez Garcia AC. The microbiology of Moxifloxacin. Drugs of Today 2000;36:215-27
4. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 1999;44:835-8
5. Gehanno P, Darantière S, Dubreuil C, Chobaut JC, Bobin S, Pages JC, et al. A prospective multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002;49:821-6
6. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, et al. Pharmacokinetics of a once/day oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxyquinolone. Antimicrob Agents Chemother 1999;43:2793-7
7. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: A review of microbiologic and pharmacokinetic-pharmaco-dynamic characteristics. Pharmacotherapy 2000;20:245-56
8. Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs of Today 2000;36:229-44
9. Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-25
10. Kaiser L, Lew D, Hirschel B, Auckenthaler R, Morabia A, Heald A, et al. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 1996;47:1507-10
11. Ahuja GS, Thompson J. What role for antibiotics in otitis media and sinusitis? Postgrad Med 1998;104:93-9,103-4
12. Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double-blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Br Med J 1996;31:325-9
13. Van Buchem FL, Knottnerus JA, Schrijnemaekers VJJ, Peeters MF. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 1997;349:683-7
14. Fairbanks DNF. Inflammatory diseases of the sinuses: Bacteriology and antibiotics. Otolaryngol Clin North Am 1993;26:549-59
15. Brook I, Yocum P, Frazier EH. Bacteriology and β-lactamase activity in acute and chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1996;122:418-23
16. Wise R. Antibiotics for the uncommon cold. Lancet 1996;347:1499
17. Fung CP, Powell M, Seymour A, Yuan M, Williams JD. The antimicrobial susceptibility of M catarrhalis isolated in England and Scotland in 1991. J Antimicrob Chemother 1992;30:47-55
18. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activity of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992-93. Antimicrob Agents Chemother 1994;38:2419-25
19. Westergren V, Nilsson M, Forsum U. Penetration of antibiotics in diseased antral mucosa. Arch Otolaryngol Head Neck Surg 1996;122:1390-4
20. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicentre randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72
21. Baz MN, Jannetti W, Villanueva C, Burke T, Pause C, Wang L., et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Ther Trends 1999;17:303-19
22. Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjoback D, Ibanez JM, Hampel B, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime-axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337-44
23. Benedict CR. The QT interval and drug-associated torsades de pointes. Drug Invet 1993;5:69-79
24. Lee KL, Jim M-H, Tang SC, Tai Y-T. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:395-6
25. Jaillon P, Morganroth J, Brumpt I, Talbot G, and the Sparfloxacin Safety Group. Overview of electrocardiagraphic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996;37(suppl. A):161-7